Skip to search formSkip to main contentSkip to account menu

tildrakizumab

National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

MK-3222

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis – efficacy findings up to week 12
Abstract Background It is challenging to select the most appropriate biologic treatment for patients with moderate-to-severe… 
2019
2019
LB0002 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE, PHASE 2B STUDY TO DEMONSTRATE THE SAFETY AND EFFICACY OF TILDRAKIZUMAB, A HIGH-AFFINITY ANTI-INTERLEUKIN-23P19 MONOCLONAL ANTIBODY…
Background Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved for moderate-to-severe… 
2019
2019
Tildrakizumab for Moderate-to-Severe Plaque Psoriasis
Psoriasis is an immune-mediated inflammatory skin condition associated with many comorbidities and poor quality of life. The… 
Review
2019
Review
2019
Update on Tildrakizumab for Psoriasis
Tildrakizumab, a humanized IgG1κ monoclonal antibody that inhibits the p19 subunit of interleukin (IL-)23, is FDA approved for… 
2018
2018
Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis
Abstract not available. Disclosures:  Study sponsored by SUN PHARMA. Copyright SKIN 2018 
Review
2018
Review
2018
Tildrakizumab: monoclonal antibody against IL-23p19 for moderate to severe psoriasis.
Tildrakizumab is a monoclonal antibody that binds to the p19 subunit of interleukin (IL)-23. Studies examining affected skin in… 
2018
2018
Clinical Efficacy or Tildrakizumab in Patients with Chronic Plaque Psoriasis Over 2 Years of Treatment: Results from Long-Term Extensions to 2 Phase 3 Clinical Studies
Kim Papp,1 Kristian Reich,2 Andrew Blauvelt,3 Diamant Thaçi,4 Rodney Sinclair,5 Stephen K Tyring,6 Nicole Cichanowitz,7 Stuart… 
2018
2018
AB0903 Efficacy of tildrakizumab in etanercept partial or nonresponders
Background Etanercept (ETN) is an anti–tumour necrosis factor (TNF) medication that was among the first biologics approved for… 
2016
2016
FRI0445 Tildrakizumab Treatment Improved Measures of Psoriatic Arthritis in Adults with Chronic Plaque Psoriasis
Background Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis. Recent evidence with biologic… 
2015
2015
Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects.
OBJECTIVE To evaluate the effect of ethnicity on the pharmacokinetics (PK) of tildrakizumab, a novel anti-IL-23 monoclonal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)